The global HER2 Targeting ADC Drugs market size is predicted to grow from US$ 7811 million in 2025 to US$ 14054 million in 2032; it is expected to grow at a CAGR of 8.5% from 2026 to 2032.

In 2025, global HER2 Targeting ADC Drugs reached approximately 6.99 M Units, with an average global market price of around 1143 USD per Unit.

HER2 Targeting ADC Drugs (HER2-targeted antibody?drug conjugates) are a class of targeted cancer medicines that use an anti-HER2 monoclonal antibody to recognize and bind tumor cells with HER2 overexpression, amplification, or certain HER2-driven biology, and then deliver a highly potent cytotoxic payload into (and sometimes around) those cells. Structurally, they are built from three essential parts: (1) the HER2 antibody (the ?homing? component), (2) a chemical linker (designed to be stable in blood but release the payload under specific conditions), and (3) the payload (a cell-killing drug such as a microtubule inhibitor or topoisomerase I inhibitor). After binding HER2, the ADC is typically internalized and processed so the payload can be released to damage critical cellular machinery and trigger cancer cell death; depending on the payload/linker properties, some HER2 ADCs can also produce a bystander effect, meaning the released payload may diffuse to kill nearby tumor cells that have lower HER2 expression.

HER2 Targeting ADC Drugs fuse the validated targeting precision of anti-HER2 antibodies with the tumor-killing power of highly potent payloads, offering a pragmatic way to overcome two persistent oncology pain points at once: the limited durability of benefit from many standard targeted agents once resistance emerges, and the systemic toxicity that often constrains conventional chemotherapy. By using HER2 as a delivery address, these conjugates can concentrate cytotoxic exposure inside cancer cells and?depending on linker and payload design?extend activity into heterogeneous tumors through bystander killing, which is increasingly important as clinicians recognize that clinically meaningful HER2 biology exists beyond the classic ?HER2-positive? bucket. Looking forward, the category?s market potential is supported by broad applicability across major solid tumors, steady innovation that improves therapeutic index through smarter linkers, controlled conjugation, and next-generation payloads, and the likelihood that HER2 ADCs will become central ?backbone? options that can be sequenced with, or paired alongside, endocrine therapy, immunotherapy, and other targeted agents?positioning the space for sustained expansion without relying on unrealistic expectations.

The core raw materials for HER2 Targeting ADC Drugs mainly include anti-HER2 antibodies, linkers, and auxiliary materials. Typical suppliers include Roche, Daiichi Sankyo, Merck, Thermo Fisher, etc. The downstream applications are mainly in the treatment of diseases such as breast cancer.

The production capacity of HER2 Targeting ADC Drugs varies greatly depending on the antibody production, conjugation process, quality control, and supply chain support. The gross profit margin of HER2 Targeting ADC Drugs is in the range of 70%-80%.

United States market for HER2 Targeting ADC Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for HER2 Targeting ADC Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for HER2 Targeting ADC Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key HER2 Targeting ADC Drugs players cover Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Infinity Market Research newest research report, the ?HER2 Targeting ADC Drugs Industry Forecast? looks at past sales and reviews total world HER2 Targeting ADC Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected HER2 Targeting ADC Drugs sales for 2026 through 2032. With HER2 Targeting ADC Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HER2 Targeting ADC Drugs industry.

This Insight Report provides a comprehensive analysis of the global HER2 Targeting ADC Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HER2 Targeting ADC Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global HER2 Targeting ADC Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HER2 Targeting ADC Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HER2 Targeting ADC Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of HER2 Targeting ADC Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Trastuzumab Type
    Non-trastuzumab Type
    Segmentation by HER2 Expression Level:
    HER2 Positive
    HER2 Low Expression
    Segmentation by Antibody:
    Monoclonal Antibody
    Bispecific Antibody
    Others

Segmentation by Application:

    Breast Cancer
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Roche
    AstraZeneca
    Daiichi Sankyo
    Remegen
    Jiangsu Hengrui Medicine
    Shanghai Henlius Biotech
    Sichuan Kelun-Biotech Biopharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global HER2 Targeting ADC Drugs market?
What factors are driving HER2 Targeting ADC Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HER2 Targeting ADC Drugs market opportunities vary by end market size?
How does HER2 Targeting ADC Drugs break out by Type, by Application?